Price
No data yet.
Social Signal Score
Revenue
$5.64M+79352.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aras Azadian Mba
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 112
- Beta
- 0.33
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.92
Financials
Revenue
$5.64M+79352.9%Net Income
$-1.02MEBITDA
$-917.5KFree Cash Flow
$-1.33MEPS (diluted)
$-0.01Shares Outstanding (diluted)
126.24M+1171.8%Operating Expenses
$4.08MCash & Debt
$200.5KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $25.46M | $-2.84M | $-0.02 |
| 2024 | $25.46M | $-3.62M | $-0.04 |
| 2023 | $16.79M | $-8.74M | $-0.10 |
| 2022 | $4.05M | $-14.74M | $-0.25 |
| 2021 | $3.27M | $-16.77M | $-0.41 |
| 2020 | $1.57M | $-32.86M | $-1.12 |
| 2019 | $168.3K | $-21.07M | $-1.05 |
| 2018 | $118.0K | $-7.10M | $-0.45 |
| 2017 | $26.7K | $-2.60M | $-0.19 |
| 2016 | $0.00 | $-29.8K | $-0.00 |
Valuation
AVCNFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·21d ago·Neutral
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026 TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada
View source ↗ - Newsglobenewswire.com·48d ago·Negative
Avicanna Announces Closing of Strategic Non-Brokered Private Placement Strategic investment by pharmaceutical executive and life sciences investor Michael Porter Strategic investment by pharmaceutical executive and life sciences investor Michael Porter
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Avicanna Reports Q2 2026 Financial Results Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.03 per share
Typical surprise +82.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.01 vs $-0.03beat
- Wed, May 13$-0.00 vs $-0.03beat
- Mon, Nov 17$-0.01 vs $-0.02beat
- Thu, Aug 14$-0.00 vs $-0.03beat
- Wed, May 14$0.00 vs $-0.04beat
- Wed, Nov 13$-0.01 vs $-0.03beat
Estimates and results for AVCNF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in AVCNF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.